| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Astrocytoma; Biliary Tract Neoplasms; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours | Details |
| Ranosidenib | HMPL-306 | Phase 3 Clinical | Glioma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours | Details | |
| TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours | Details |
| MT-001 | MT-001; MT001 | Phase 2 Clinical | Zhejiang Meton Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Leukemia, Myeloid, Acute; Solid tumours | Details |
| IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Glioma; Leukemia, Myeloid, Acute; Neoplasms | Details |
| IDH1/2 inhibitor (Eli Lilly) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Glioma; Solid tumours | Details |
| KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
| HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Chondrosarcoma; Glioma; Solid tumours | Details |
| LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Cholangiocarcinoma; Chondrosarcoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ivosidenib | CS-3010; S-95031; CS 3010; AG-120 | Approved | Agios Pharmaceuticals Inc | 拓舒沃, Tidhesco, Tibsovo, TIBSOVO, Tuoshuvo, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Bile Duct Neoplasms; Cholangiocarcinoma; Chondrosarcoma; Ependymoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Medulloblastoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Myeloid; Solid tumours; Wilms Tumor | Details |
| Vorasidenib | AG-881; AGI-23088; S-95032; S95032 | Approved | Agios Pharmaceuticals Inc | VORANIGO | United States | Astrocytoma; Oligodendroglioma; Glioma | Servier Pharmaceuticals Llc, Laboratoires Servier | 2024-08-06 | Astrocytoma; Ganglioglioma; Glioblastoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Liver Diseases; Liver Dysfunction; Myelodysplastic Syndromes; Oligodendroglioma | Details |
| Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Diarrhea; Irritable Bowel Syndrome; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes | Details |